Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Assets (2019 - 2025)

Historic Current Assets for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $206.9 million.

  • C4 Therapeutics' Current Assets fell 2428.89% to $206.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $921.9 million, marking a year-over-year decrease of 1619.54%. This contributed to the annual value of $257.8 million for FY2024, which is 494.93% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Current Assets is $206.9 million, which was down 2428.89% from $224.7 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Current Assets high stood at $477.6 million for Q2 2021, and its period low was $206.9 million during Q3 2025.
  • Over the past 5 years, C4 Therapeutics' median Current Assets value was $278.5 million (recorded in 2023), while the average stood at $293.2 million.
  • Per our database at Business Quant, C4 Therapeutics' Current Assets soared by 9734.16% in 2021 and then plummeted by 3333.52% in 2022.
  • Over the past 5 years, C4 Therapeutics' Current Assets (Quarter) stood at $325.7 million in 2021, then fell by 11.71% to $287.6 million in 2022, then decreased by 5.69% to $271.2 million in 2023, then decreased by 4.95% to $257.8 million in 2024, then dropped by 19.75% to $206.9 million in 2025.
  • Its Current Assets was $206.9 million in Q3 2025, compared to $224.7 million in Q2 2025 and $232.5 million in Q1 2025.